Artivion

AORT · NYSE

$23.09+$0.81 (+3.64%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $22.28

AORT analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $42.99 (+86.2% upside)

Low: $38.38
Now: $23.09
High: $50.40

Upgrades and downgrades

The latest rating actions, newest first

AORT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Oct 20, 2026	Initiates	Buy	$31.00	40%
Canaccord Genuity	Aug 18, 2026	Maintains	Buy	$39.00 → $40.00	44%
Needham	Jul 20, 2026	Maintains	Buy	$44.00	45%
Canaccord Genuity	Jun 16, 2026	Maintains	Buy	$36.00	44%
Citizens	May 8, 2026	Maintains	Market Outperform	$53.00 → $48.00	36%
Needham	May 8, 2026	Maintains	Buy	$58.00 → $44.00	45%
Ladenburg Thalmann	Apr 10, 2026	Upgrade	Neutral → Buy	$42.00	50%
Needham	Apr 7, 2026	Maintains	Buy	$58.00	45%
Canaccord Genuity	Feb 13, 2026	Maintains	Buy	$51.00 → $48.00	44%
Needham	Feb 2, 2026	Maintains	Buy	$58.00	45%

The case for and against

Updated Oct 21, 2026

Bull case

Artivion is positioned for durable growth because its aortic-centric portfolio is being expanded by AMDS and NEXUS, while On-X is benefiting from stronger clinical data and a larger addressable market. The 1Q26 guidance reset appears tied to temporary factors—supplier capacity, AMDS commercialization friction, and softer Middle Eastern sales—rather than weakening procedure demand, and AMDS now has full FDA approval in June 2026, which should broaden adoption by removing IRB requirements. It also continues to improve profitability, with EBITDA margin rising from 13.3% to 20.3% from 2022 to 2025 and management expecting 20%+ EBITDA growth in 2027E and 2028E, supported by high-margin products and operating leverage.

Bear case

Artivion is exposed to a heavy mix of operational and regulatory risks that weaken its fundamental outlook, especially since non-North American revenue was 49% of total company revenue in 2024 and depends on continued global expansion that is vulnerable to tariffs, corruption exposure, reimbursement changes, and legal constraints. Its tissue preservation services are also a major revenue source, but supply limitations, negative publicity, disease-transmission concerns, and tighter US and foreign regulations could disrupt volumes and distribution. On top of that, the company faces product recall risk, EU MDR transition risk, possible FDA reclassification of SGPV to Class III, and EtO sterilization scrutiny, while management has already flagged slower growth from disappointing new product launches and weaker international expansion.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.